Acutaas Chemicals Limited (NSE: ACUTAAS | BSE: 543349)

By Raveendran R | Updated on:

Source: Acutaas Chemicals Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners

Acutaas Chemicals Limited (formerly known as Ami Organics Limited) is a Gujarat-headquartered, multi-vertical specialty chemicals enterprise built on over two decades of process chemistry expertise. The company operates as a research and development (R&D)-led manufacturer, transitioning from a generic active pharmaceutical ingredient (API) intermediate specialist into a diversified technology platform.

CORE BUSINESS SEGMENTS:
  • Advanced Pharmaceutical Intermediates: Encompasses 500+ commercial products and 160+ global customers. Over 95% of the pharma intermediate portfolio is targeted toward chronic therapeutic areas (including cardiovascular, anti-psychotic, anti-depressant, anti-neoplastic, anti-retroviral, and non-steroidal anti-inflammatory applications). Key molecules are fully backward integrated up to N-1 process stages, providing 50% to 90% global market share in critical generic intermediates.
  • CDMO Platform: The innovator custom development franchise validated 4 new NCE/CDMO molecules during FY 2025-26 alongside its anchor long-term supply contract with Fermion. The development pipeline added 30 to 40 new molecules during the year, advancing projects from early-stage synthesis to multi-ton late-stage clinical and commercial manufacturing.
  • Battery Chemicals Division: Inaugurated Phase 1 at the Jhagadia complex in January 2026, establishing 2,000 MTPA installed capacity for Vinylene Carbonate (VC) and 2,000 MTPA for Fluoroethylene Carbonate (FEC). The entire Phase 1 commercial capacity is secured under 3-year long-term off-take customer contracts. The division maintains a development pipeline of 10+ battery additive products.
  • Semiconductor Chemicals Division: Operated via Baba Fine Chemicals (1.8 KL reaction capacity in Greater Noida) and Indichem Inc. (South Korea). It manufactures extreme ultra-purity electronic-grade photoresist chemicals, etchants, and specialized polymer precursors operating at parts-per-billion (PPB) purity specifications.
Metrics for FY 2025-26 Ended Mar 31, 2026
PROFIT & LOSS METRICS (₹ CR)
Revenue
₹1,339.37 Cr (▲ 33.0%)
Prev Year: ₹1,006.88 Cr
Gross Profit
₹773.41 Cr (▲ 70.1%)
Prev Year: ₹454.70 Cr
Operating Profit
₹444.41 Cr (▲ 116.3%)
Prev Year: ₹205.48 Cr
Net Profit
₹356.37 Cr (▲ 122.1%)
Prev Year: ₹160.42 Cr
Gross Margin
57.74 % (▲ 1259 bps)
Prev Year: 45.16 %
Operating Margin
33.18 % (▲ 1277 bps)
Prev Year: 20.41 %
PAT Margin
26.61 % (▲ 1067 bps)
Prev Year: 15.93 %
Asset Turnover
0.68x (▲ 0.03 pts)
Prev Year: 0.65x
RETURN & CAPITAL EFFICIENCY METRICS
ROE
20.83 % (▲ 868 bps)
Prev Year: 12.15 %
ROCE
25.35 % (▲ 1009 bps)
Prev Year: 15.25 %
ROA
17.96 % (▲ 761 bps)
Prev Year: 10.35 %
Cash ROE
17.08 % (▲ 811 bps)
Prev Year: 8.96 %
Cash ROCE
16.67 % (▲ 788 bps)
Prev Year: 8.79 %
BALANCE SHEET METRICS (₹ CR)
Total Assets
₹1,983.96 Cr (▲ 28.1%)
Prev Year: ₹1,549.26 Cr
Current Assets
₹881.27 Cr (▲ 11.3%)
Prev Year: ₹791.64 Cr
Total Liabilities
₹273.21 Cr (▲ 19.2%)
Prev Year: ₹229.18 Cr
Current Liabilities
₹230.81 Cr (▲ 14.1%)
Prev Year: ₹202.25 Cr
Total Equity
₹1,710.75 Cr (▲ 29.6%)
Prev Year: ₹1,320.08 Cr
Working Capital
₹650.46 Cr (▲ 10.4%)
Prev Year: ₹589.39 Cr
Current Ratio
3.82x (▼ 0.10 pts)
Prev Year: 3.91x
Total Debt
₹35.60 Cr (▲ 175.3%)
Prev Year: ₹12.93 Cr
Debt to Equity
0.02x (▲ 0.01 pts)
Prev Year: 0.01x
Debt to Assets
0.02x (▲ 0.01 pts)
Prev Year: 0.01x
Equity Multiplier
1.16x (▼ 0.01 pts)
Prev Year: 1.17x
CASH FLOW METRICS (₹ CR)
Operating Cash Flow
₹292.17 Cr (▲ 146.9%)
Prev Year: ₹118.34 Cr
CapEx
₹327.98 Cr (▲ 68.5%)
Prev Year: ₹194.64 Cr
Free Cash Flow
-₹35.81 Cr (▲ 53.1%)
Prev Year: -₹76.30 Cr
FCF Margin
-2.67 % (▲ 490 bps)
Prev Year: -7.58 %
CF to Debt
8.21x (▼ 0.95 pts)
Prev Year: 9.15x
ROCE (3Y Avg)
18.57 %
FY24–FY26 (3Y Avg)
ROE (3Y Avg)
14.13 %
FY24–FY26 (3Y Avg)
Cash ROCE (3Y Avg)
11.93 %
FY24–FY26 (3Y Avg)
Cash ROE (3Y Avg)
12.50 %
FY24–FY26 (3Y Avg)

📋 Quick Facts / Company Snapshot: Acutaas Chemicals Limited (NSE: ACUTAAS | BSE: 543349)

Attribute Disclosed Detail
Official Company Name Acutaas Chemicals Limited
Corporate Identity Number (CIN) L24100GJ2007PLC051093
International Securities Identification Number (ISIN) INE00FF01025
Stock Exchange Listing NSE: ACUTAAS | BSE: 543349
Date of Incorporation / Founding Year Formed as a partnership firm in 2004; Incorporated as a Private Limited Company on June 12, 2007; Rebranded to Acutaas Chemicals Limited in May 2025
Founders / Key Founding Figures Mr. Nareshkumar Ramjibhai Patel & Mr. Chetankumar Chhaganlal Vaghasia
Registered Office & Corporate Headquarters Plot No. 440/4, 5 & 6, Road No. 82/A, GIDC Sachin, Surat – 394 230, Gujarat, India
Telephone & Investor Email +91 75730 15366 / +91 72279 77744 | investorinfo@acutaas.com
Chairman & Managing Director Mr. Nareshkumar Ramjibhai Patel (Executive Chairman & Managing Director)
CFO & Company Secretary Mr. Bhavin N. Shah (Chief Financial Officer) | Mrs. Ekta Kumari Srivastava (Company Secretary & Compliance Officer)
Promoter & Holding Group Patel & Vaghasia Promoter Family (Nareshkumar R. Patel & Chetankumar C. Vaghasia)
Industry / Sector Classification Specialty Chemicals & Advanced Pharmaceutical Intermediates (NIC Code: 20119)
Total Employees & Workforce Structure 1,007 Total On-Roll Employees (940 Permanent Employees, 67 Permanent Workers, 706 Contractual Workers)
Manufacturing Facilities & Operating Footprint 5 Facilities across 2 Countries (Sachin, Ankleshwar, Jhagadia in Gujarat, India; Greater Noida, UP, India; Gongju, South Korea – Under Construction)
Credit Ratings & Rating Agency CARE Ratings Limited: Long-Term Bank Facilities rated CARE A+ (Stable); Short-Term Bank Facilities rated CARE A1+
Statutory, Secretarial, Cost & Internal Auditors Statutory: M/s Maheshwari & Co. | Secretarial: M/s KSPS & Co. LLP | Cost: M/s Chirag Vallabhbhai Vekariya & Co. | Internal: M/s K. C. Mehta & Co. LLP
Registrar and Share Transfer Agent (RTA) MUFG Intime India Private Limited (Formerly Link Intime India Private Limited), C-101, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai – 400083

🏢 The Corporate Identity: Acutaas Chemicals Overview, Promoters & History

The Big Picture: Business Model & Core Value Proposition

Acutaas Chemicals Limited (formerly known as Ami Organics Limited) is a Gujarat-headquartered, multi-vertical specialty chemicals enterprise built on over two decades of process chemistry expertise. The company operates as a research and development (R&D)-led manufacturer, transitioning from a generic active pharmaceutical ingredient (API) intermediate specialist into a diversified technology platform. Its core business spans advanced pharmaceutical intermediates, New Chemical Entity (NCE) development, semiconductor photoresist chemicals, battery electrolyte additives, and fine specialty chemicals.

The company’s commercial architecture operates on deep backward integration, with over 90% of its key pharmaceutical products derived internally from basic industrial feedstocks. By developing multi-step complex synthesis platforms—including continuous flow chemistry, microreactors, UV photochemistry, and slurry flow systems—Acutaas maintains dominant global market shares ranging from 50% to 90% in its anchor intermediate molecules. Its business model addresses four high-conviction end markets:

  • Advanced Pharmaceutical Intermediates & CDMO: Catering primarily to fast-growing chronic therapeutic segments (cardiovascular, central nervous system, anti-diabetic, and oncology), supplying global innovator drug manufacturers and generic API producers.
  • Semiconductor Chemicals: Operating through its majority-owned subsidiary Baba Fine Chemicals and South Korean joint venture Indichem Inc. to produce parts-per-billion (PPB) ultra-high-purity photoresist chemicals and electronic-grade processing agents.
  • Battery Chemicals: Functioning as India’s pioneer commercial manufacturer of non-China sourced lithium-ion battery electrolyte additives, specifically Vinylene Carbonate (VC) and Fluoroethylene Carbonate (FEC).
  • Specialty & Fine Chemicals: Upgrading legacy commodity product lines (such as parabens and methyl salicylate) into higher-margin, customer-qualified specialty chemical solutions.

The Founders, Promoters & Their Legacy

The operational and strategic leadership of Acutaas Chemicals Limited is anchored by its co-founders, Mr. Nareshkumar Ramjibhai Patel and Mr. Chetankumar Chhaganlal Vaghasia. Beginning as a modest partnership firm in 2004, the founders guided the enterprise through technical scale-ups, global regulatory accreditations, equity capital market listings, and international joint ventures.

  • Mr. Nareshkumar Ramjibhai Patel (Executive Chairman & Managing Director): Promoted to lead the executive board, Mr. Patel brings over two decades of technical and commercial experience in process chemistry, market expansion, and capital allocation. Under his leadership, Acutaas expanded its global presence to over 55 countries and secured strategic partnerships with major innovator pharmaceutical conglomerates. He holds 1,44,83,327 equity shares (17.69% equity stake) in the company as of March 31, 2026.
  • Mr. Chetankumar Chhaganlal Vaghasia (Executive Director): Co-founder of the organization, Mr. Vaghasia possesses 23 years of experience in specialty chemical manufacturing, supply chain logistics, human resource governance, and plant operations. He directly oversees human resources, procurement, IT, and dispatch operations across the group’s facilities. He holds 1,22,58,079 equity shares (14.97% equity stake) in the company as of March 31, 2026.

The Journey: Corporate History & Key Milestones

The evolutionary trajectory of Acutaas Chemicals Limited highlights a transition from lab-scale synthesis to an multi-plant industrial platform:

  • 2004–2007: Founded as Ami Organics, a partnership firm; incorporated as Ami Organics Private Limited in June 2007 with its initial manufacturing unit in Sachin, Gujarat.
  • 2011–2017: Received DSIR accreditation for its in-house R&D center; secured initial USFDA EIR (Establishment Inspection Report) for the Sachin facility; expanded warehousing and raw material storage infrastructure.
  • 2018–2020: Acquired manufacturing facilities at Ankleshwar and Jhagadia from Gujarat Organics Limited; secured PMDA Japan Good Manufacturing Practice (GMP) certification for Unit 1 (Sachin) and Unit 2 (Ankleshwar); commissioned a centralized R&D center and solvent recovery facility.
  • 2021: Successfully completed a landmark Initial Public Offering (IPO) and listed equity shares on the NSE and BSE.
  • 2022–2023: Acquired a 55% controlling partnership stake in Baba Fine Chemicals, entering the semiconductor photoresist chemicals sector; established wholly-owned subsidiary Ami Organics Electrolytes Private Limited; commissioned a automated brownfield facility at Ankleshwar equipped with Distributed Control System (DCS) technology.
  • 2024–2025: Awarded EcoVadis Gold and subsequently EcoVadis Platinum accreditation (ranking in the top 1% of assessed companies globally); completed equity share sub-division (1:2 stock split); formed Indichem Inc., a 75:25 joint venture in South Korea with J & Materials Co. Ltd. to construct an advanced semiconductor chemical facility in Gongju.
  • 2025–2026: Officially rebranded from Ami Organics Limited to Acutaas Chemicals Limited; inaugurated Phase 1 of the commercial battery chemicals project at Jhagadia (2,000 MTPA capacity each for VC and FEC); achieved certified Great Place To Work® status and received Responsible Care certification from the Indian Chemical Council.

The Corporate Umbrella & Group Structure

Acutaas Chemicals Limited exercises governance over an international network of subsidiaries, step-down entities, partnership firms, and joint ventures designed to isolate specific sector capabilities:

  • Acutaas Advance Material Limited (Formerly Baba Advance Materials Limited): Wholly-owned Indian subsidiary executing strategic investments and capital allocations for the group’s semiconductor initiatives.
  • Acutaas Chemicals Electrolytes Private Limited (Formerly Ami Organics Electrolytes Private Limited): Indian subsidiary dedicated to manufacturing and commercializing battery chemicals and electrolyte additives (holding 100% equity stake through FY26, diluted to 90% in May 2026).
  • Baba Fine Chemicals: Partnership firm in Greater Noida, UP, in which Acutaas holds a 55% controlling economic interest, serving as India’s sole domestic manufacturer of ultra-high-purity photoresist chemicals.
  • Indichem Inc.: Step-down foreign subsidiary incorporated in Gongju, South Korea (75% equity held via Acutaas Advance Material Limited and 25% by J & Materials Co. Ltd.) constructing a semiconductor chemicals production hub and operating an active R&D center.
  • Enchem Ami Organics Private Limited: Step-down domestic subsidiary focused on battery chemical commercialization.
  • Ami Onco-Theranostics, LLC: 50:50 joint venture entity registered in Delaware, USA, focusing on oncology therapeutic research.

⚙️ The Business Engine: Acutaas Chemicals Segments, Brands, Products & Operations

The Core Divisions & Segment Revenue Breakdown

Acutaas Chemicals Limited categorizes its business operations into two principal primary business segments under Ind AS 108: Advanced Pharmaceutical Intermediates and Specialty Chemicals. In FY 2025-26, total consolidated revenue from operations expanded by 33.02% year-on-year to reach ₹1,339.37 Crores, driven by the commercial scaling of its Contract Development and Manufacturing Organisation (CDMO) franchise.

Business Vertical / Division FY 2025-26 Revenue (₹ Cr) % Share of Total Revenue FY 2024-25 Revenue (₹ Cr) Latest YoY (%)
Advanced Pharmaceutical Intermediates 1,174.10 87.66% 854.10 +37.47%
Specialty Chemicals (Commodity, Semi & Battery) 165.00 12.32% 152.70 +8.06%
Other Operating Revenue 10.40 0.78% 6.91 +50.51%
Total Revenue from Operations 1,339.37 100.00% 1,006.88 +33.02%

The Product & Service Catalog (with Operational KPIs, Order Book & Customer Concentration)

The enterprise maintains a catalog of over 610 commercialized products sold to approximately 600 global customers across 55 countries. The operational backbone comprises a total installed reaction volume of ~1,100 KL across four multi-purpose Indian operational sites, supplemented by dedicated tonnage-scale continuous lines.

  • Advanced Pharmaceutical Intermediates: Encompasses 500+ commercial products and 160+ global customers. Over 95% of the pharma intermediate portfolio is targeted toward chronic therapeutic areas (including cardiovascular, anti-psychotic, anti-depressant, anti-neoplastic, anti-retroviral, and non-steroidal anti-inflammatory applications). Key molecules are fully backward integrated up to N-1 process stages, providing 50% to 90% global market share in critical generic intermediates.
  • CDMO Platform: The innovator custom development franchise validated 4 new NCE/CDMO molecules during FY 2025-26 alongside its anchor long-term supply contract with Fermion. The development pipeline added 30 to 40 new molecules during the year, advancing projects from early-stage synthesis to multi-ton late-stage clinical and commercial manufacturing.
  • Battery Chemicals Division: Inaugurated Phase 1 at the Jhagadia complex in January 2026, establishing 2,000 MTPA installed capacity for Vinylene Carbonate (VC) and 2,000 MTPA for Fluoroethylene Carbonate (FEC). The entire Phase 1 commercial capacity is secured under 3-year long-term off-take customer contracts. The division maintains a development pipeline of 10+ battery additive products.
  • Semiconductor Chemicals Division: Operated via Baba Fine Chemicals (1.8 KL reaction capacity in Greater Noida) and Indichem Inc. (South Korea). It manufactures extreme ultra-purity electronic-grade photoresist chemicals, etchants, and specialized polymer precursors operating at parts-per-billion (PPB) purity specifications.
  • Commodity Fine Chemicals: Portfolio of 30+ products serving 400+ customers across 55 countries, producing fine chemical preservatives, parabens, methyl salicylate, and para-anisic acid, which are systematically being transitioned toward higher-margin technical applications.
  • Sourcing & Customer Concentration: Raw material sourcing is highly localized, with 59% of inputs procured domestically within India, insulating operations from global maritime freight shocks. In compliance with Ind AS 108 disclosures, no single external customer accounted for more than 10% of total consolidated revenue in FY 2025-26.

The Names You Know: Key Brands & Flagship Portfolio

Brand / Product Name Category / Business Segment Target Market & Key Positioning
Vinylene Carbonate (VC) Battery Chemicals Lithium-ion electrolyte additive enhancing cell life, thermal stability, and SEI layer formation.
Fluoroethylene Carbonate (FEC) Battery Chemicals High-voltage electrolyte additive for silicon-anode lithium-ion batteries and EV energy storage.
Photoresist Monomers & PAGs Semiconductor Chemicals Ultra-high-purity (PPB level) photochemical agents used in semiconductor wafer lithography.
N-1 Chronic Pharma Intermediates Pharmaceutical Intermediates Advanced multi-step precursors for cardiovascular, CNS, and anti-diabetic generic APIs.
Parabens & Methyl Salicylate Specialty Fine Chemicals Preservatives and active fine ingredients for global personal care, cosmetic, and pharma formulations.

Mapping the Domestic & Global Reach (India vs. Exports)

Acutaas Chemicals Limited maintains a global commercial footprint, deriving over three-quarters of its operational revenues from foreign export markets. The company exports to ~55 countries, with major sales destinations including North America, Europe, Japan, South Korea, Taiwan, and Southeast Asia.

Geographic Region FY 2025-26 Revenue (₹ Cr) % Share of Total Revenue FY 2024-25 Revenue (₹ Cr) Latest YoY (%)
International / Exports 1,021.34 76.26% 742.59 +37.54%
Domestic (India) 307.63 22.97% 257.38 +19.52%
Other Operating Income 10.40 0.78% 6.91 +50.51%
Total Revenue from Operations 1,339.37 100.00% 1,006.88 +33.02%

The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices

The group operates five specialized manufacturing facilities and an accredited central research facility covering a total land area exceeding 92,835 square meters:

  • Unit 1 (Sachin, Surat, Gujarat): 8,250 sq. mt. land area; 144 KL installed reactor capacity across 40 reactors, 17 dryers, and 13 production lines. Operates a Zero Liquid Discharge (ZLD) effluent treatment plant and Soil Biotechnology (SBT) system; USFDA EIR and PMDA GMP certified.
  • Unit 2 (Ankleshwar, Gujarat): 10,375 sq. mt. land area; 442 KL installed reactor capacity across 80+ reactors. Fully automated multi-purpose plant operating on Distributed Control System (DCS) and Powder Transfer System (PTS) automation; PMDA Japan GMP certified.
  • Unit 3 (Jhagadia, Bharuch, Gujarat): 56,698 sq. mt. land area; 512 KL reactor capacity (31 stainless steel and 14 glass-lined reactors) dedicated to fine specialty chemicals, alongside live Phase 1 battery chemicals capacity (2,000 MTPA VC and 2,000 MTPA FEC). Runs an advanced ETP and holds ISO-K Nuclear certification.
  • Unit 4 (Greater Noida, Uttar Pradesh – Baba Fine Chemicals): 999 sq. mt. land area; 1.8 KL specialized reaction volume across 7 clean-room lab blocks. India’s single production base for electronic-grade photoresist chemicals.
  • Unit 5 (Gongju, South Korea – Indichem Inc. JV): 16,513 sq. mt. land area; ultra-high-purity semiconductor chemical manufacturing asset currently under construction (slated for H2 CY2026 commissioning), supported by an active local R&D sampling center.
  • Central R&D Center (Sachin, Surat): 2,200 sq. mt. DSIR-approved innovation center housing 130+ R&D staff (including 30+ PhD scientists), 4 advancement laboratories with 30 fume hoods, an 8-reactor automated pilot plant, and 43+ distinct chemical reaction capabilities.
  • Renewable Energy Generation Asset (Vahelam, Bharuch & Narmada): 15.8 MW captive solar power infrastructure generating 52% of the total annual electricity consumed across the Ankleshwar and Jhagadia operating units.

📊 The Financial Health: Acutaas Chemicals Financial Statements & Numbers Simplified

Multi-Year Financial Highlights (₹ in Crores)

The multi-year financial performance reflects consistent revenue growth, operational leverage, and balance sheet expansion over a three-year period:

Financial Metric FY 2025-26 FY 2024-25 FY 2023-24 Latest YoY (%)
Revenue from Operations 1,339.37 1,006.88 717.50 +33.02%
Operating EBITDA 480.40 232.10 128.50 +106.98%
EBITDA Margin (%) 35.87% 23.05% 17.91% –
Profit Before Tax (PBT) 482.73 216.16 114.00 +123.32%
Profit After Tax (PAT) 356.37 160.42 80.80 +122.15%
PAT Margin (%) 26.61% 15.93% 11.26% –
Total Equity / Net Worth 1,710.75 1,320.08 858.90 +29.59%
Capital Employed (Adjusted) 1,753.15 1,347.01 950.40 +30.15%
Return on Equity (RoE – Adjusted) (%) 20.83% 12.15% 11.40% –
Return on Capital Employed (RoCE – Adjusted) (%) 25.35% 15.25% 15.10% –
Operating Cash Flow 292.17 118.34 98.40 +146.89%

Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)

Consolidated Statement of Profit and Loss Line Item FY 2025-26 (₹ Cr) FY 2024-25 (₹ Cr) Latest YoY (%)
Revenue from Operations 1,339.37 1,006.88 +33.02%
Other Income 41.59 16.93 +145.66%
TOTAL INCOME 1,380.95 1,023.80 +34.88%
Cost of Materials Consumed 594.96 569.81 +4.41%
Changes in Inventories of Finished Goods & WIP (29.00) (17.63) +64.49%
Employee Benefits Expense 117.57 83.66 +40.53%
Finance Costs 3.27 6.22 -47.43%
Depreciation and Amortization Expense 35.99 26.62 +35.20%
Other Expenses 175.44 138.96 +26.25%
TOTAL EXPENSES 898.23 807.64 +11.22%
PROFIT BEFORE TAX (PBT) 482.73 216.16 +123.32%
Current Tax Expense 117.20 49.19 +138.26%
Deferred Tax Expense 9.16 6.56 +39.63%
PROFIT AFTER TAX (PAT) 356.37 160.42 +122.15%
Profit Attributable to Owners of the Company 356.26 158.71 +124.47%
Profit Attributable to Non-Controlling Interests 0.11 1.70 -93.53%
Other Comprehensive Loss (Net of Tax) (3.22) (0.14) +2200.00%
TOTAL COMPREHENSIVE INCOME FOR THE YEAR 353.14 160.28 +120.33%

Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)

ASSETS: Non-Current AssetsCurrent AssetsEQUITY AND LIABILITIES: EquityNon-Current LiabilitiesCurrent Liabilities
Consolidated Balance Sheet Line Item FY 2025-26 (₹ Cr) FY 2024-25 (₹ Cr) Latest YoY (%)
Property, Plant and Equipment 582.80 462.92 +25.90%
Capital Work-in-Progress (CWIP) 332.32 130.28 +155.08%
Right-of-Use Assets 50.52 42.39 +19.18%
Goodwill 104.34 56.80 +83.70%
Intangible Assets 7.19 8.28 -13.16%
Non-Current Financial Assets – Investments 0.20 0.20 0.00%
Other Non-Current Financial Assets (Security Deposits) 8.22 4.93 +66.73%
Non-Current Income Tax Assets (Net) 0.00 0.15 -100.00%
Other Non-Current Assets (Capital Advances) 17.10 51.67 -66.91%
Total Non-Current Assets 1,102.69 757.63 +45.54%
Inventories 231.32 179.94 +28.55%
Trade Receivables 362.56 290.49 +24.81%
Cash and Cash Equivalents 215.55 185.22 +16.38%
Bank Balances Other than Cash & Cash Equivalents 9.28 63.70 -85.43%
Current Financial Assets – Loans 2.60 2.16 +20.37%
Other Current Assets 59.95 70.11 -14.49%
Total Current Assets 881.27 791.64 +11.32%
TOTAL ASSETS 1,983.96 1,549.26 +28.06%
Equity Share Capital 40.94 40.93 +0.02%
Other Equity 1,612.63 1,268.69 +27.11%
Equity Attributable to Owners of the Company 1,653.56 1,309.63 +26.26%
Non-Controlling Interests 57.19 10.45 +447.27%
Total Equity (Net Worth) 1,710.75 1,320.08 +29.59%
Non-Current Financial Liabilities – Lease Liabilities 9.11 4.75 +91.79%
Non-Current Provisions 4.59 2.55 +80.00%
Deferred Tax Liabilities (Net) 28.71 19.63 +46.26%
Total Non-Current Liabilities 42.40 26.93 +57.45%
Current Borrowings (Short-Term Loans) 26.49 8.18 +223.84%
Trade Payables – MSME Dues 27.18 54.32 -49.96%
Trade Payables – Other Creditors 126.72 101.72 +24.58%
Other Current Liabilities 12.44 13.48 -7.72%
Current Provisions 32.50 24.54 +32.44%
Current Tax Liabilities (Net) 5.48 0.00 N/M
Total Current Liabilities 230.81 202.25 +14.12%
Total Liabilities (Excluding Equity) 273.21 229.18 +19.21%
TOTAL EQUITY AND LIABILITIES 1,983.96 1,549.26 +28.06%

Working Capital Cycle & Schedule III Statutory Ratio Explanations

Working capital efficiency remained steady during FY 2025-26, with the net working capital cycle shifting modestly from 114 days to 120 days despite a 33.02% scale-up in operational turnover.

Statutory Financial Ratio FY 2025-26 FY 2024-25 Management Explanation for Variance >25% Latest YoY (%)
Current Ratio 3.82x 3.91x Variability within normal operating range. -2.30%
Debt-Equity Ratio 0.02x 0.01x Slight increase in working capital credit utilization. +100.00%
Debt Service Coverage Ratio (DSCR) 120.06x 30.08x Significant expansion in operating cash earnings available for debt servicing. +299.14%
Return on Equity (RoE) 20.83% 12.15% Higher net profitability driven by CDMO margin expansion. –
Inventory Turnover Ratio 6.51x 5.98x Higher production and finished goods throughput. +8.86%
Trade Receivables Turnover Ratio 4.10x 4.05x Consistent collection timelines across export markets. +1.23%
Trade Payables Turnover Ratio 3.84x 3.92x Stable procurement settlement practices. -2.04%
Net Capital Turnover Ratio 2.20x 1.79x Higher revenue generation per rupee of net working capital. +22.91%
Net Profit Ratio (%) 356.37 15.70% Substantial improvement in product mix and CDMO volume realization. –
Return on Capital Employed (RoCE) 25.35% 15.25% Higher EBIT contribution relative to capital base. –

Cash Flow: Tracking the Money Movement

Consolidated Cash Flow Statement Activity FY 2025-26 (₹ Cr) FY 2024-25 (₹ Cr) Latest YoY (%)
Profit Before Tax (PBT) 482.73 216.16 +123.32%
Operating Profit Before Working Capital Changes 496.86 235.09 +111.35%
Net Working Capital Adjustments (93.12) (69.01) +34.94%
Direct Income Taxes Paid (Net) (111.57) (46.74) +138.70%
Net Cash Generated from Operating Activities (A) 292.17 118.34 +146.89%
Purchase of Property, Plant & Equipment / CWIP / Intangibles (327.98) (194.64) +68.51%
Net Redemption / (Placement) of Bank Fixed Deposits 54.42 (40.10) N/M
Interest Received & Investment Adjustments 7.62 10.80 -29.44%
Net Cash Used in Investing Activities (B) (265.94) (223.94) +18.76%
Net Proceeds / (Repayment) of Short-Term Borrowings 18.31 (94.82) N/M
Repayment of Long-Term Debt / Lease Liabilities (0.66) (113.98) -99.42%
Equity Share Capital & Premium Issued / QIP Proceeds 0.01 499.39 -100.00%
Finance Costs & Share Issue Expenses Paid (1.28) (17.19) -92.55%
Equity Dividend Paid (12.28) (12.28) 0.00%
Net Cash Generated from / (Used in) Financing Activities (C) 4.10 261.12 -98.43%
NET INCREASE / (DECREASE) IN CASH & CASH EQUIVALENTS (A+B+C) 30.33 155.52 -80.50%
Cash & Cash Equivalents at Beginning of the Year 185.22 29.70 +523.64%
Cash & Cash Equivalents at End of the Year 215.55 185.22 +16.38%

Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange

The company executes a phased investment program spanning FY2023 through FY2030. Key highlights of CapEx, research commitments, and foreign exchange intensity include:

  • Capital Expenditure & CWIP Deployment: Total capital expenditure deployed in FY 2025-26 reached ₹195.00 Crores (with gross cash additions to PPE and CWIP standing at ₹327.98 Crores). The capital outlay was directed toward Phase 1 of the Jhagadia battery chemicals facility, pilot plant expansion at Sachin, and captive solar assets. Capital Work-in-Progress (CWIP) as of March 31, 2026, stood at ₹332.32 Crores.
  • R&D Expenditure Intensity: Total R&D expenditure for FY 2025-26 stood at ₹22.76 Crores (comprising ₹17.59 Crores in recurring revenue expenditure and ₹5.17 Crores in capital R&D investments), representing 1.72% of standalone operational revenue.
  • Net Foreign Exchange Earnings (Section 134(3)(m)): On a standalone basis, total foreign exchange inflows (export proceeds) reached ₹968.34 Crores, while total foreign exchange outflows (raw material imports and capital goods) stood at ₹267.60 Crores, generating net foreign exchange earnings of ₹700.74 Crores.

👥 Power & Control: Acutaas Chemicals Governance, Leadership & Shareholding Pattern

The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)

The governance structure of Acutaas Chemicals Limited is overseen by an 8-member Board of Directors, comprising 50% Independent Directors (including 2 Women Independent Directors).

Name of Director / KMP Designation / Role DIN Category
Nareshkumar Ramjibhai Patel Executive Chairman & Managing Director 00906232 Promoter Executive Director
Chetankumar Chhaganlal Vaghasia Executive Director 01375540 Promoter Executive Director
Virendranath Mishra Whole Time Director 07815490 Executive Director
Ram Mohan Lokhande Whole Time Director 08117035 Executive Director
Girikrishna S. Maniar Independent Director (Audit Committee Chair) 07515981 Non-Executive Independent Director
Hetal Madhukant Gandhi Independent Director (NRC Committee Chair) 00106895 Non-Executive Independent Director
Richa Manoj Goyal Independent Director (SRC & CSR Chair) 00159889 Non-Executive Independent Director
Dr. Anita Bandyopadhyay Independent Director 08672071 Non-Executive Independent Director
Bhavin N. Shah Chief Financial Officer (CFO) KMP Key Managerial Personnel
Ekta Kumari Srivastava Company Secretary & Compliance Officer KMP Key Managerial Personnel

Who Owns the Stock? Shareholding Pattern

As of March 31, 2026, the paid-up share capital of the company stood at ₹40,93,55,610 divided into 8,18,71,122 equity shares of face value ₹5 each. Institutional investors (Foreign Portfolio Investors, Mutual Funds, Insurance Companies, and AIFs) collectively hold 39.08% of the equity capital.

Shareholder Category Number of Equity Shares Held % of Total Issued Equity Capital
Promoter & Promoter Group 2,67,41,416 32.66%
Foreign Portfolio Investors (FPIs / Corporate) 1,59,52,201 19.48%
Mutual Funds 1,13,47,656 13.86%
Insurance Companies 26,61,506 3.25%
Alternate Investment Funds (AIFs) 20,37,472 2.49%
Government Pension Fund Global 29,01,687 3.54%
Public / Non-Institutional Shareholders & Others 2,02,29,184 24.72%
Total Issued Equity Shares 8,18,71,122 100.00%

🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities

Subsidiaries, Associates, & Joint Ventures (Form AOC-1)

The corporate family tree encompasses domestic subsidiaries, foreign operating step-down entities, partnership firms, and international joint ventures (financial figures as reported in Form AOC-1 in ₹ Crores):

Entity Name Relationship Type Country % Shareholding FY 2025-26 Turnover (₹ Cr) FY 2025-26 Net PAT (₹ Cr)
Acutaas Chemicals Electrolytes Pvt. Ltd. Wholly-Owned Subsidiary India 100.00%* 0.02 (3.73)
Acutaas Advance Material Limited Wholly-Owned Subsidiary India 100.00% 0.00 (2.12)
Baba Fine Chemicals Partnership Entity India 55.00% 15.59 3.25
Indichem Inc. Step-Down Foreign JV South Korea 75.00% 0.19 (5.39)
Enchem Ami Organics Private Limited Step-Down Subsidiary India 100.00% 0.00 (0.00)
Ami Onco-Theranostics, LLC Joint Venture USA 50.00% 0.00 0.00

*Holding diluted to 90% in May 2026. **Held via Acutaas Advance Material Limited.

Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities

  • Strategic Treasury Investments: Holds non-current equity investments in environmental infrastructure projects, including Globe Enviro Care Limited (74,171 shares; ₹0.10 Crore), Narmada Cleantech Limited (82,176 shares; ₹0.09 Crore), Sachin Industrial Co-Operative Society (3,012 shares; ₹0.004 Crore), and Bharuch Enviro Infrastructure Limited (1,260 shares; ₹0.001 Crore). Total unquoted carrying value stands at ₹0.20 Crore.
  • Credit Ratings Profile: Rated by CARE Ratings Limited. Long-term bank facilities (term loans/facilities) are rated CARE A+ with a Stable outlook; short-term bank facilities (working capital/trade facilities) are assigned CARE A1+.
  • Banking Consortium: Working capital and credit facilities are maintained across Axis Bank Limited, HDFC Bank Limited, ICICI Bank Limited, and DBS Bank Limited.
  • Contingent Liabilities & Capital Commitments: Total estimated capital commitments remaining to be executed (net of capital advances) stood at ₹39.44 Crores as of March 31, 2026 (down from ₹80.27 Crores in FY25). Off-balance sheet bank guarantees issued by lenders stood at ₹1.33 Crores.

🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs

Competitive Advantages & Economic Moats

  • Process Chemistry Moat & Backward Integration: Over 90% of key active intermediates are backward integrated from basic industrial feedstocks. Process engineering capabilities—spanning 43+ reaction chemistry classes, flow reactors, and UV photochemistry—enable market share leadership (50% to 90%) in key global intermediate molecules.
  • First-Mover Non-China Battery Chemicals Platform: India’s pioneer commercial manufacturer of non-FEOC (ex-China) compliant electrolyte additives (Vinylene Carbonate and Fluoroethylene Carbonate). With Phase 1 capacity fully contracted for 3 years, Acutaas is positioned to supply global battery cell gigafactories expanding under the US Inflation Reduction Act / FEOC guidelines and India’s ACC PLI scheme.
  • Semiconductor Hub Footprint via South Korea: India’s sole commercial manufacturer of electronic-grade photoresist chemicals (Baba Fine Chemicals). The Gongju, South Korea joint venture (Indichem Inc.) places the company directly inside the semiconductor ecosystem anchored by Samsung and SK Hynix, enabling ‘Just-in-Time’ local technical validation.
  • High Entry Barriers & Global Regulatory Accreditations: Manufacturing facilities hold active USFDA Establishment Inspection Reports (EIR) and PMDA Japan GMP certifications without critical audit observations, complemented by 21 CFR-compliant QA systems, ISO certifications, and EcoVadis Platinum rating.

What Could Go Wrong? Key Challenges & Business Risks

  • Geopolitical Shipping & Feedstock Disruption: Geopolitical friction in the Middle East and the closure of the Strait of Hormuz present risk to global maritime logistics, extending Gulf-Asia transit times by 8 to 12 days and increasing chemical feedstock import costs.
  • Capex Execution & Customer Off-Take Timelines: Multi-year CapEx deployments in South Korea (Indichem Inc.) and Jhagadia Phase 2 battery chemicals entail project execution, equipment lead-time, and customer qualification risks before revenue generation.
  • Customer Concentration in Emerging Verticals: Early-stage operations in battery chemicals and semiconductor materials rely on a concentrated group of tier-1 customers, where qualification delays could impact asset turnover.

The Next Chapter: Growth, Order Pipeline & CapEx Initiatives

The strategic agenda for FY 2026-27 and beyond focuses on expanding the high-margin CDMO franchise while scaling commercial production across newly commissioned specialty verticals:

  • CDMO Franchise Expansion: Following the validation of 4 new CDMO products during FY 2025-26, the pipeline includes 30 to 40 additional molecules progressing toward clinical scale-up. The company is investing ₹25.00 Crores to construct a high-potent API (HPAPI) pilot plant at Sachin to support late-stage NCE projects.
  • Commercialization of Battery Additives Phase 1 & Phase 2 Expansion: Phase 1 capacity at Jhagadia (2,000 MTPA VC and 2,000 MTPA FEC) is ramping up commercial production backed by 3-year off-take agreements. Phase 2 expansion is progressing to introduce two additional electrolyte additive molecules during FY 2026-27.
  • Commissioning of South Korean Semiconductor Asset: Indichem Inc.’s manufacturing facility in Gongju, South Korea, is scheduled for commercial commissioning in H2 CY2026, transitioning from sample evaluation to full commercial supply for leading East Asian semiconductor fabs.
  • Electronic Grade Chemicals Expansion: The Board of Directors on August 22, 2026, approved a new CapEx program of up to ₹212.00 Crores to build up to 81,000 MTPA of new electronic-grade chemical manufacturing capacity.

The Verdict: Strategic Outlook & Conclusion

Acutaas Chemicals Limited has successfully evolved from a specialized domestic intermediate manufacturer into a global specialty chemistry platform. By maintaining capital discipline—allocating CapEx primarily against contracted demand—the enterprise achieved its highest-ever adjusted Return on Capital Employed (RoCE) of 39.30% and Return on Equity (RoE) of 32.50% in FY 2025-26, while maintaining a healthy balance sheet with net cash position of ₹198.30 Crores. With four growth drivers—Pharma CDMO, Battery Chemicals, Semiconductor Materials, and Specialty Fine Chemicals—Acutaas is positioned to capitalize on global supply chain diversification across healthcare and advanced technology industries.

Frequently Asked Questions (FAQs) About Acutaas Chemicals

Q1: What does Acutaas Chemicals Limited manufacture, and what are its core products?

Acutaas Chemicals Limited manufactures advanced pharmaceutical intermediates, New Chemical Entity (NCE) custom synthesis products, semiconductor photoresist chemicals, lithium-ion battery electrolyte additives, and fine specialty chemicals. Its key commercial products include Vinylene Carbonate (VC), Fluoroethylene Carbonate (FEC), electronic-grade photoresist monomers, N-1 chronic pharma intermediates, parabens, and methyl salicylate.

Q2: What were Acutaas Chemicals’ revenue and net profit in FY 2025-26?

In FY 2025-26, Acutaas Chemicals Limited reported consolidated revenue from operations of ₹1,339.37 Crores (a growth of 33.02% year-on-year compared to ₹1,006.88 Crores in FY 2024-25) and a consolidated Profit After Tax (PAT) of ₹356.37 Crores (a growth of 122.15% compared to ₹160.42 Crores in FY 2024-25).

Q3: Who are the promoters and Managing Director of Acutaas Chemicals Limited?

The company was co-founded by Mr. Nareshkumar Ramjibhai Patel (Executive Chairman & Managing Director) and Mr. Chetankumar Chhaganlal Vaghasia (Executive Director). The promoter family collectively holds a 32.66% equity stake in the company as of March 31, 2026.

Q4: Where are Acutaas Chemicals’ manufacturing facilities located, and what is its export share?

The company operates five manufacturing facilities: Unit 1 in Sachin (Surat, Gujarat), Unit 2 in Ankleshwar (Gujarat), Unit 3 in Jhagadia (Gujarat), Unit 4 in Greater Noida (Uttar Pradesh via Baba Fine Chemicals), and Unit 5 in Gongju (South Korea via Indichem Inc., under construction). In FY 2025-26, exports accounted for 76.26% of total operational revenues, serving customers in ~55 countries.

Q5: What is Acutaas Chemicals’ debt profile, credit rating, and net worth?

Acutaas Chemicals maintains a debt-light balance sheet with total short-term borrowings of ₹26.49 Crores and lease liabilities of ₹9.11 Crores, against total cash and cash equivalents (including bank balances) of ₹224.83 Crores (yielding a net cash position of ₹198.30 Crores). Total consolidated Equity (Net Worth) stood at ₹1,710.75 Crores as of March 31, 2026. Long-term bank facilities are rated CARE A+ (Stable) and short-term facilities are rated CARE A1+ by CARE Ratings Limited.

Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.

Official Site: https://www.acutaas.com